Shares of Vericel VCEL remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share rose 30.00% year over year to ($0.07), which missed the estimate of ($0.04).
Revenue of $34,568,000 higher by 29.57% year over year, which beat the estimate of $32,050,000.
Outlook
The upcoming fiscal year's revenue expected to be between $165,000,000 and $168,000,000.
How To Listen To The Conference Call
Date: May 05, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/tmaohhkc
Recent Stock Performance
52-week high: $64.89
52-week low: $12.82
Price action over last quarter: Up 24.34%
Company Profile
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
